Anesthesia drugs market to be worth $8.93 billion in 2028, report says

28 April 2022
anasthesia_anaesthesia_2022_large

The global anesthesia drugs market was valued at $6.8 billion in 2020.

By 2028, it will be worth $8.93 billion, having grown at a compound annual growth rate of nearly 3.5%, according to a report from Strategic Market Research.

The report forecasts that general anesthesia drugs will dominate this market during the period in question, and key players will include AbbVie (NYSE: ABBV), Aspen Pharmacare (JSE: APN) AstraZeneca (LSE: AZN), Baxter International (NYSE: BAX) and Boehringer Ingelheim.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical